Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/17151
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Willison, Donald J. (Donald Jon) | en_US |
dc.contributor.author | Centre for Health Economics and Policy Analysis | en_US |
dc.coverage.spatial | Canada | en_US |
dc.coverage.spatial | Canada | en_US |
dc.coverage.spatial | Canada | en_US |
dc.coverage.spatial | Canada | en_US |
dc.coverage.spatial | Canada | en_US |
dc.coverage.spatial | Canada | en_US |
dc.coverage.spatial | Canada | en_US |
dc.date.accessioned | 2015-04-14T14:42:04Z | - |
dc.date.available | 2015-04-14T14:42:04Z | - |
dc.date.issued | 2001 | en_US |
dc.identifier.uri | http://www.chepa.org/portals/0/pdf/01-08.pdf | en_US |
dc.identifier.uri | http://hdl.handle.net/11375/17151 | - |
dc.description | Donald J. Willison. | en_US |
dc.description | Bibliography: p. 30-35. | en_US |
dc.description | Also available via World Wide Web. | en_US |
dc.description.abstract | Pharmaceuticals are the focus of increased scrutiny by public insurers. Between 1985 and 1998, drug expenditure in Canada increased by 226%-approximately double the increase in total expenditure on health. Prescribed and non-prescribed drugs now comprise the second-largest share of health care expenditures after hospitals, surpassing physicians' services. The National Forum on Health called for common strategies across the provinces, to manage pharmaceuticals from a health policy perspective. At the same time, the federal government and several provinces are interested in promoting pharmaceutical research and development (R&D), as part of the advancement of a knowledge-based economy. In the past, debates about pharmaceutical policy centred on the balancing of cost-containment and access to needed pharmaceuticals. | en_US |
dc.description.abstract | The creation of an environment more conducive to attracting pharmaceutical R&D introduces additional tensions that will, no doubt, require concessions in current policies to manage pharmaceutical expenditures. In addition, a significant R&D investment will have predictable "downstream" effects on other sectors, such as academic research. In this study, we describe the experience of 7 Western industrialized countries in controlling pharmaceutical budgets while maintaining access to medically necessary prescription medications. In addition, we describe the potential impact of these policies on pharmaceutical R&D and the efforts of these countries to create a favourable climate for fostering R&D within their borders. We identify tensions that arise between health policy and industrial policy goals, and broad questions of directions and choices. | en_US |
dc.format.extent | 57 p. | en_US |
dc.publisher | McMaster University, Centre for Health Economics and Policy Analysis | en_US |
dc.relation.ispartofseries | CHEPA working paper series 01-08 | en_US |
dc.subject | Economics, Pharmaceutical | en_US |
dc.subject | Drug and Narcotic Control | en_US |
dc.subject | Insurance, Pharmaceutical Services | en_US |
dc.subject | Drug Costs | en_US |
dc.subject | Prescription Drugs | en_US |
dc.subject | economics | en_US |
dc.subject | National Health Programs | en_US |
dc.subject | Health Expenditures | en_US |
dc.title | International experience with pharmaceutical policy | en_US |
dc.type | text | en_US |
Appears in Collections: | CHEPA Working Paper Series |
Files in This Item:
There are no files associated with this item.
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.